N-acetyltransferase 2 acetylation polymorphism: Prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects

Skin Pharmacology and Applied Skin Physiology

Volumn 16, Issue 6, 2003, Pages 386-392

  Brocvielle, H ^a   Muret, P ^a   Goydadin, A C ^a   Boone, P ^b   Broly, F ^b   Kantelip, J P ^a   Humbert, P ^a,c  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINT JACQUES   (France)

Author keywords

Atopic dermatitis; N acetyltransferase 2; Slow acetylation

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; DAPSONE; PRIMER DNA; UNCLASSIFIED DRUG;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; ALLELE; ALLERGIC DISEASE; ARTICLE; ATOPIC DERMATITIS; CAUCASIAN; CHROMOSOME MUTATION; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; WILD TYPE;

ACETYLATION; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; DAPSONE; DERMATITIS, ATOPIC; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KINETICS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0141993228     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072934     Document Type: Article

References (16)

1. Sim E, Payton M, Noble M, Minchin R: An update on genetic, structural and functional studies of arylamine N-acetyltransferases in euca-ryotes and procaryotes. Hum Mol Genet 2000;9:2435-2441.
2. Arylamine N-Acetyltransferase (EC 2.3.1.5) Nomenclature (last update august 27, 2002). www.louisville.edu/medschool/pharmacology/ NAT.html.
3. Evans DA: An improved and simplified method of detecting the acetylator phenotype. J Med Genet 1969;6:405-407.
4. Ellard GA: Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976;19:610-625.
5. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA: Role of N-ace-tyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;ii:842-845.
6. Orzechowska-Juzwenko K, Milejski P, Patkowski J, Nittner-Marszalska M, Malolepszy J: Acetylator phenotype in patients with allergic diseases and its clinical significance. Int J Clin Pharmacol Ther Toxicol 1990;28:420-425.
7. Zielinska E, Niewiarowski W, Bodalski J, Stanczyk A, Bolanowski W, Rebowski G: Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997;62:635-642.
8. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G: Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 1999;65:562-569.
9. Luszawska-Kutrzeba T: NAT2* genotype in children with bronchial asthma and other atopic diseases. Ann Acad Med Stetin 1999;45:109-121 [in Polish].
10. Von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, Golka K, Richter-Hintz D, Schuppe HC, Leh-mann P, Ruzicka T, Esser C, Abel J: Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 1999;455:147-152.
11. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B: Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997;36:1089-1094.
12. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M: A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995;5:255-258.
13. Horai Y, Ishizaki T: Rapid and sensitive liquid chromatographic method for the determination of dapsone and monoacetyldapsone in plasma and urine. J Chromatogr 1985;345:447-452.
14. Blum M, Demierre A, Grant DM, Heim M, Meyer UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-5241.
15. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, et al: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
16. Hein DW, Grant DM, Sim E: Up-date on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000;10:291-292.